jrnls.org logo
Submit

BROWSE ALL JOURNALS

Type 2 letters to search all 19 journals

SEE ALL 19 JOURNALS
Indian Journal of Pharmaceutical Education and ResearchNOW IN
Back

IJPER · Lens · Development and Characterization of Ranolazine-Loaded Solid Lipid Nanoparticles for Enhanced Angina Therapy

PDF

Article · Volume 60, Issue 4 · pp. 1409–1415

Development and Characterization of Ranolazine-Loaded Solid Lipid Nanoparticles for Enhanced Angina Therapy

Prasanna Shirgaonkar1, Rutuja Chougale2, Kiran Patil1, Vibhuti Thakur1, Firoj Tamboli3, Somnath Bhinge4, Shailendra Gurav5

  1. 1Department of Pharmaceutical Quality Assurance, Tatyasaheb Kore College of Pharmacy, Warananagar, Warana University, Warananagar, Kolhapur, Maharashtra, INDIA.
  2. 2Department of Pharmaceutics, Bharati Vidyapeeth College of Pharmacy, Near Chitranagari, (Affiliated to Shivaji University), Kolhapur, Maharashtra, INDIA.
  3. 3Department of Pharmacognosy, Bharati Vidyapeeth College of Pharmacy, Near Chitranagari (Affiliated to Shivaji University), Kolhapur, Maharashtra, INDIA.
  4. 4Department of Pharmaceutical Quality Assurance, Krishna Institute of Pharmacy, Krishna Vishwa Vidyapeeth (Deemed to be University), Karad, Maharashtra, INDIA.
  5. 5Department of Pharmacognosy and Phytochemistry, Goa College of Pharmacy, Goa University, Goa, INDIA.

Abstract

Background: The study focuses on the development and characterization of Ranolazine-loaded Solid Lipid Nanoparticles (RNZ-SLNs) to enhance therapeutic efficacy and safety in angina therapy.Materials and Methods: RNZ-SLNs were synthesized using a heated homogenization process followed by ultrasonication. The formulation was characterized for particle size, zeta potential, % entrapement efficiency, and in vitro drug release profile. Biocompatibility was evaluated using in vitro hemolysis studies. Results and Discussion: The results of the study demonstrated that the formulated Ranolazine-loaded Solid Lipid Nanoparticles (RNZ-SLNs) exhibited favorable physicochemical properties essential for effective drug delivery. The particle size of the RNZ-SLNs was found to be 254.1±2.4 nm, indicating their suitability for nanoparticle-based drug delivery systems. The zeta potential of -15.3±1.8 mV reflected sufficient stability of the formulation, while the % entrapement efficiency of 75.15±3.1% confirmed the effective incorporation of Ranolazine within the lipid matrix. The in vitro drug release profile revealed a significantly enhanced release rate for RNZ-SLNs, achieving 61.807±2.51% over 24 hr, compared to the plain Ranolazine dispersion, which released only 36.807±2.08% within the same period. Furthermore, in vitro hemolysis studies indicated a marked improvement in biocompatibility for RNZ-SLNs, with a hemolytic effect of 9.17%, compared to 19.23% observed for plain Ranolazine. These findings collectively highlight the potential of RNZ-SLNs to improve the therapeutic efficacy and safety profile of Ranolazine for angina therapy.Conclusion: RNZ-SLNs demonstrated superior therapeutic potential, including improved drug release and biocompatibility, suggesting their promise as an effective and safe delivery system for Ranolazine in angina therapy.

Keywords: Angina; Pluronic F108; Ranolazine; Solid lipid nanoparticles; Stearic acid

The full text of this article is available as a PDF. Open the PDF.